An Examination of the Clinical Benefits and Cost-Effectiveness of Tocolytic Replacement Following Recurrent Preterm Labor

ABSTRACT

We examined pregnancy outcomes in women receiving nifedipine tocolysis having recurrent preterm labor (RPTL). Singleton gestations enrolled for outpatient nursing surveillance and prescribed nifedipine tocolysis were identified (n = 4748). Women hospitalized for RPTL at <35 weeks then resuming outpatient surveillance were included (n = 1366). Pregnancy outcomes of women resuming nifedipine (n = 830) were compared with those having an alteration in treatment to continuous subcutaneous terbutaline (n = 536). Overall, 56.7% (2692/4748) experienced RPTL. Half (50.7%) were stabilized and resumed outpatient surveillance with nifedipine or continuous subcutaneous terbutaline. Infants from women resuming nifedipine versus those with alteration of treatment to terbutaline were more likely to deliver at <35 weeks (28.0% versus 13.8%), weigh <2500 g (32.9% versus 20.3%), and require a stay in the neonatal intensive care unit (34.0% versus 23.1%), all p < 0.001. Alteration of tocolytic treatment following RPTL resulted in a decreased incidence of preterm birth and low birth weight, resulting in less admission to the neonatal intensive care unit and fewer nursery days.

KEYWORDS

Preterm labor - tocolysis - continuous subcutaneous terbutaline - nifedipine

REFERENCES

• 1 Raju T N, Higgins R D, Stark A R, Leveno K J. Optimizing care and outcome for late-preterm (near-term) infants: a summary of the workshop sponsored by the National Institute of Child Health and Human Development.  Pediatrics. 2006;  118 1207-1214
• 2 Goldenberg R L, Culhane J F, Iams J D, Romero R. Epidemiology and causes of preterm birth.  Lancet. 2008;  371 75-84
• 3 Gazmararian J A, Petersen R, Jamieson D J et al.. Hospitalizations during pregnancy among managed care enrollees.  Obstet Gynecol. 2002;  100 94-100
• 4 Iams J D, Johnson F F, Hamer C. Uterine activity and symptoms as predictors of preterm labor.  Obstet Gynecol. 1990;  76(1 suppl) 42S-46S
• 5 ACOG Committee on Practice Bulletins. American College of Obstetricians and Gynecologist . ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologist. Number 43, May 2003. Management of preterm labor.  Obstet Gynecol. 2003;  101(5 Pt 1) 1039-1047
• 6 Sanchez-Ramos L, Kaunitz A M, Gaudier F L, Delke I. Efficacy of maintenance therapy after acute tocolysis: a meta-analysis.  Am J Obstet Gynecol. 1999;  181 484-490
• 7 Carr D B, Clark A L, Kernek K, Spinnato J A. Maintenance oral nifedipine for preterm labor: a randomized clinical trial.  Am J Obstet Gynecol. 1999;  181 822-827
• 8 de la Torre L, Istwan N B, Desch C et al.. Management of recurrent preterm labor in twin gestations with nifedipine tocolysis.  Am J Perinatol. 2008;  25 555-560
• 9 Lyell D J, Pullen K M, Mannan J et al.. Maintenance nifedipine tocolysis compared with placebo: a randomized controlled trial.  Obstet Gynecol. 2008;  112 1221-1226
• 10 Lam F, Gill P J, Smith M, Kitzmiller J L, Katz M. Use of the subcutaneous terbutaline pump for long-term tocolysis.  Obstet Gynecol. 1988;  72 810-813
• 11 Lam F, Gill P. beta-Agonist tocolytic therapy.  Obstet Gynecol Clin North Am. 2005;  32 457-484
• 12 Guinn D A, Goepfert A R, Owen J, Wenstrom K D, Hauth J C. Terbutaline pump maintenance therapy for prevention of preterm delivery: a double-blind trial.  Am J Obstet Gynecol. 1998;  179 874-878
• 13 Wenstrom K D, Weiner C P, Merrill D, Niebyl J. A placebo controlled randomized trial of the terbutaline pump for prevention of preterm delivery.  Am J Perinatol. 1997;  14 87-91
• 14 Fleming A, Bonebrake R, Istwan N, Rhea D, Coleman S, Stanziano G. Pregnancy and economic outcomes in patients treated for recurrent preterm labor.  J Perinatol. 2004;  24 223-227
• 15 Lam F, Istwan N B, Jacques D, Coleman S K, Stanziano G J. Managing perinatal outcomes: the clinical benefit and cost-effectiveness of pharmacologic treatment of recurrent preterm labor.  Manag Care. 2003;  12 39-46
• 16 Morrison J C, Chauhan S P, Carroll Sr C S, Bofill J A, Magann E F. Continuous subcutaneous terbutaline administration prolongs pregnancy after recurrent preterm labor.  Am J Obstet Gynecol. 2003;  188 1460-1465 discussion 1465-1467
• 17 Gilbert W M, Nesbitt T S, Danielsen B. The cost of prematurity: quantification by gestational age and birth weight.  Obstet Gynecol. 2003;  102 488-492
• 18 Pryde P G, Besinger R E, Gianopoulos J G, Mittendorf R. Adverse and beneficial effects of tocolytic therapy.  Semin Perinatol. 2001;  25 316-340
• 19 Pryde P G, Janeczek S, Mittendorf R. Risk-benefit effects of tocolytic therapy.  Expert Opin Drug Saf. 2004;  3 639-654
• 20 Kim A, Shim J-Y. Emerging tocolytics for maintenance therapy of preterm labour: oxytocin antagonists and calcium channel blockers.  BJOG. 2006;  113(suppl 3) 113-115
• 21 Hill W C. Risks and complications of tocolysis.  Clin Obstet Gynecol. 1995;  38 725-745
• 22 Elliott J P, Istwan N B, Rhea D, Stanziano G. The occurrence of adverse events in women receiving continuous subcutaneous terbutaline therapy.  Am J Obstet Gynecol. 2004;  191 1277-1282
• 23 Abenhaim H A, Tremblay V, Tremblay L, Audibert F. Feasibility of a randomized controlled trial testing nifedipine vs. placebo for the treatment of preterm labor.  J Perinat Med. 2007;  35 301-304